Leiomyosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major leiomyosarcoma markets are expected to exhibit a CAGR of 3.3% during 2024-2034.
The leiomyosarcoma market has been comprehensively analyzed in IMARC's new report titled "Leiomyosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leiomyosarcoma is a type of cancer that originates from smooth muscle cells. Smooth muscles are found in various body organs and tissues, such as the uterus, gastrointestinal tract, blood vessels, skin, etc. The symptoms of the ailment can vary depending on the size and location of the tumor, but common signs may include pain or discomfort in the affected area, the presence of a palpable mass or swelling, unexplained weight loss, fatigue, and, in some cases, symptoms related to compression or invasion of adjacent organs or structures. The diagnosis of leiomyosarcoma involves a combination of imaging studies and a biopsy. Several imaging techniques, including computed tomography (CT) scans and magnetic resonance imaging (MRI), help visualize the tumor and assess its characteristics and extent. A biopsy is then performed to obtain a tissue sample for histopathological examination, where a pathologist examines the sample under a microscope to confirm the presence of malignant smooth muscle cells. Several additional molecular pathology tests, such as immunohistochemistry and genetic analysis, may be conducted to further characterize the tumor and guide treatment decisions.
The increasing cases of certain genetic conditions, including hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, which is characterized by the development of leiomyomas (benign smooth muscle tumors), are primarily driving the leiomyosarcoma market. Moreover, the escalating adoption of locoregional therapies to help control tumor growth and extend survival in patients with locally advanced or recurrent leiomyosarcoma is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of various image-guided biopsies, such as CT-guided or ultrasound-guided biopsies, since they allow for precise sampling of the tumor while minimizing the risk of complications, is creating a positive outlook for the market. Furthermore, numerous key players are making extensive investments in the development of several therapies that can shrink tumors and facilitate surgical removal, thereby preserving organ function and improving the chances of achieving negative surgical margins. This, in turn, is also propelling the market growth. Additionally, the ongoing advancements in immunotherapeutic approaches, including the introduction of immune checkpoint inhibitors and adoptive cell therapies, which have demonstrated promising results in subsets of leiomyosarcoma patients, particularly those with high tumor mutational burden or microsatellite instability, are expected to drive the leiomyosarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the leiomyosarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leiomyosarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leiomyosarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the leiomyosarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the leiomyosarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current leiomyosarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the leiomyosarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the leiomyosarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the leiomyosarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of leiomyosarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of leiomyosarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of leiomyosarcoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with leiomyosarcoma across the seven major markets?
What is the size of the leiomyosarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of leiomyosarcoma?
What will be the growth rate of patients across the seven major markets?
Leiomyosarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for leiomyosarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leiomyosarcoma market?
What are the key regulatory events related to the leiomyosarcoma market?
What is the structure of clinical trial landscape by status related to the leiomyosarcoma market?
What is the structure of clinical trial landscape by phase related to the leiomyosarcoma market?
What is the structure of clinical trial landscape by route of administration related to the leiomyosarcoma market?
The leiomyosarcoma market has been comprehensively analyzed in IMARC's new report titled "Leiomyosarcoma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Leiomyosarcoma is a type of cancer that originates from smooth muscle cells. Smooth muscles are found in various body organs and tissues, such as the uterus, gastrointestinal tract, blood vessels, skin, etc. The symptoms of the ailment can vary depending on the size and location of the tumor, but common signs may include pain or discomfort in the affected area, the presence of a palpable mass or swelling, unexplained weight loss, fatigue, and, in some cases, symptoms related to compression or invasion of adjacent organs or structures. The diagnosis of leiomyosarcoma involves a combination of imaging studies and a biopsy. Several imaging techniques, including computed tomography (CT) scans and magnetic resonance imaging (MRI), help visualize the tumor and assess its characteristics and extent. A biopsy is then performed to obtain a tissue sample for histopathological examination, where a pathologist examines the sample under a microscope to confirm the presence of malignant smooth muscle cells. Several additional molecular pathology tests, such as immunohistochemistry and genetic analysis, may be conducted to further characterize the tumor and guide treatment decisions.
The increasing cases of certain genetic conditions, including hereditary leiomyomatosis and renal cell cancer (HLRCC) syndrome, which is characterized by the development of leiomyomas (benign smooth muscle tumors), are primarily driving the leiomyosarcoma market. Moreover, the escalating adoption of locoregional therapies to help control tumor growth and extend survival in patients with locally advanced or recurrent leiomyosarcoma is acting as another significant growth-inducing factor. Apart from this, the emerging popularity of various image-guided biopsies, such as CT-guided or ultrasound-guided biopsies, since they allow for precise sampling of the tumor while minimizing the risk of complications, is creating a positive outlook for the market. Furthermore, numerous key players are making extensive investments in the development of several therapies that can shrink tumors and facilitate surgical removal, thereby preserving organ function and improving the chances of achieving negative surgical margins. This, in turn, is also propelling the market growth. Additionally, the ongoing advancements in immunotherapeutic approaches, including the introduction of immune checkpoint inhibitors and adoptive cell therapies, which have demonstrated promising results in subsets of leiomyosarcoma patients, particularly those with high tumor mutational burden or microsatellite instability, are expected to drive the leiomyosarcoma market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the leiomyosarcoma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for leiomyosarcoma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the leiomyosarcoma market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the leiomyosarcoma market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the leiomyosarcoma market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current leiomyosarcoma marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the leiomyosarcoma market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the leiomyosarcoma market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the leiomyosarcoma market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of leiomyosarcoma across the seven major markets?
What is the number of prevalent cases (2018-2034) of leiomyosarcoma by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of leiomyosarcoma by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with leiomyosarcoma across the seven major markets?
What is the size of the leiomyosarcoma patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of leiomyosarcoma?
What will be the growth rate of patients across the seven major markets?
Leiomyosarcoma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for leiomyosarcoma drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the leiomyosarcoma market?
What are the key regulatory events related to the leiomyosarcoma market?
What is the structure of clinical trial landscape by status related to the leiomyosarcoma market?
What is the structure of clinical trial landscape by phase related to the leiomyosarcoma market?
What is the structure of clinical trial landscape by route of administration related to the leiomyosarcoma market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LEIOMYOSARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LEIOMYOSARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LEIOMYOSARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 LEIOMYOSARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LEIOMYOSARCOMA - UNMET NEEDS
10 LEIOMYOSARCOMA - KEY ENDPOINTS OF TREATMENT
11 LEIOMYOSARCOMA - MARKETED PRODUCTS
11.1 List of Leiomyosarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Yondelis (Trabectedin) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LEIOMYOSARCOMA - PIPELINE DRUGS
12.1 List of Leiomyosarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Unesbulin - PTC Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TTI 621 - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AL 3818 - Advenchen Laboratories
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Avelumab - Merck KGaA
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. LEIOMYOSARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LEIOMYOSARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LEIOMYOSARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Leiomyosarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Leiomyosarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Leiomyosarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Leiomyosarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Leiomyosarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Leiomyosarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Leiomyosarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Leiomyosarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Leiomyosarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Leiomyosarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Leiomyosarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Leiomyosarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Leiomyosarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Leiomyosarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Leiomyosarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Leiomyosarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Leiomyosarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Leiomyosarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Leiomyosarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Leiomyosarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Leiomyosarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Leiomyosarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Leiomyosarcoma - Access and Reimbursement Overview
16 LEIOMYOSARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LEIOMYOSARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LEIOMYOSARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 LEIOMYOSARCOMA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 LEIOMYOSARCOMA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 LEIOMYOSARCOMA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 LEIOMYOSARCOMA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 LEIOMYOSARCOMA - UNMET NEEDS
10 LEIOMYOSARCOMA - KEY ENDPOINTS OF TREATMENT
11 LEIOMYOSARCOMA - MARKETED PRODUCTS
11.1 List of Leiomyosarcoma Marketed Drugs Across the Top 7 Markets
11.1.1 Yondelis (Trabectedin) - Johnson & Johnson
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 LEIOMYOSARCOMA - PIPELINE DRUGS
12.1 List of Leiomyosarcoma Pipeline Drugs Across the Top 7 Markets
12.1.1 Unesbulin - PTC Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 TTI 621 - Pfizer
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 AL 3818 - Advenchen Laboratories
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 Avelumab - Merck KGaA
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. LEIOMYOSARCOMA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. LEIOMYOSARCOMA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 LEIOMYOSARCOMA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Leiomyosarcoma - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Leiomyosarcoma - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Leiomyosarcoma - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Leiomyosarcoma - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Leiomyosarcoma - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Leiomyosarcoma - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Leiomyosarcoma - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Leiomyosarcoma - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Leiomyosarcoma - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Leiomyosarcoma - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Leiomyosarcoma - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Leiomyosarcoma - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Leiomyosarcoma - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Leiomyosarcoma - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Leiomyosarcoma - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Leiomyosarcoma - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Leiomyosarcoma - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Leiomyosarcoma - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Leiomyosarcoma - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Leiomyosarcoma - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Leiomyosarcoma - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Leiomyosarcoma - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Leiomyosarcoma - Access and Reimbursement Overview
16 LEIOMYOSARCOMA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 LEIOMYOSARCOMA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 LEIOMYOSARCOMA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
